<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237194</url>
  </required_header>
  <id_info>
    <org_study_id>N-20190071</org_study_id>
    <nct_id>NCT04237194</nct_id>
  </id_info>
  <brief_title>A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy</brief_title>
  <acronym>PacTox</acronym>
  <official_title>A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carsten Dahl Mørch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the impact of Paclitaxel treatment on the nerve excitability of the small and large&#xD;
      nerve fibers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of many&#xD;
      chemotherapeutic agents, especially antineoplastic agents. To limit the nerve damages, early&#xD;
      detection and management of CIPN is crucial and leaves an urgent demand for new diagnostic&#xD;
      tools. Perception threshold tracking has enabled assessments of nerve excitability tests of&#xD;
      both small and large sensory nerves and may be used to assess CIPN at early stages. The&#xD;
      purpose of this study is to examine whether a new nerve excitability test can detect changes&#xD;
      in the membrane properties of the small and large nerve fibers during chemotherapy treatment.&#xD;
&#xD;
      In this study nerve excitability tests will be performed with 2 different electrodes using a&#xD;
      novel perception threshold tracking technique to assess the Nerve excitability of small and&#xD;
      large fibers. Further quantitative sensory tests (QST) will be performed to estimate the&#xD;
      vibration threshold, warm and cool perception thresholds, heat and cold pain thresholds, and&#xD;
      perceived intensity to static mechanic stimulations will be assessed. Symptoms of CIPN will&#xD;
      be assessed using the Common Terminology Criteria for Adverse events scale and a Quality of&#xD;
      Life Questionnaire CIPN twenty-item scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Nerve fiber excitability</measure>
    <time_frame>The difference between baseline and the 6 months follow-up</time_frame>
    <description>The chronaxie and the rheobase to rectangular stimuli, the accommodation to triangular stimuli, and the electrotonus to subthreshold hyperpolarizing pre-pulses for large and small sensory nerves from the excitability measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Quantitative sensory test</measure>
    <time_frame>The difference between baseline and the 6 months follow-up</time_frame>
    <description>The Quantitative sensory test is a reduced version of the German protokol and contains warmth and cold detection thresholds, heat and cold pain thresholds, vibration threshold and perceived intensity to mechanical stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changed of CTCAE</measure>
    <time_frame>The difference between baseline and the 6 months follow-up</time_frame>
    <description>Common Terminology Criteria for Adverse events scale is a scale from 0 to 5, where 5 is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CIPN20.</measure>
    <time_frame>The difference between baseline and the 6 months follow-up</time_frame>
    <description>Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Twenty-Item scale is a 20-item self-report questionnaire. Items are scored 1-4 with 1 representing &quot;not at all&quot; and 4 &quot;very much.&quot; Scores are then linearly converted to a 0-100 scale where 100 is worse.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients receiving adjuvant chemotherapy, consisting of 3 cycles of&#xD;
        Epirubicin and Cyclophosphamide (EC), followed by 3 cycles of Paclitaxel (9 Paclitaxel&#xD;
        infusions).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years&#xD;
&#xD;
          2. Histopathologically verified breast cancer&#xD;
&#xD;
          3. Performance Status according to WHO/ECOG (PS) 0-2&#xD;
&#xD;
          4. Candidate for adjuvant standard treatment with EC and Paclitaxel&#xD;
&#xD;
          5. Not previously treated with chemotherapeutic agents&#xD;
&#xD;
          6. Neurological examination without pathological findings&#xD;
&#xD;
          7. Willingness to voluntarily sign an informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously neoadjuvant treatment with chemotherapy&#xD;
&#xD;
          2. Receives prophylactic bone marrow stimulants&#xD;
&#xD;
          3. HIV&#xD;
&#xD;
          4. Diabetes mellitus&#xD;
&#xD;
          5. Opioid requirement&#xD;
&#xD;
          6. Symptomatic neurosensory disorders&#xD;
&#xD;
          7. Neurological diseases, such as sclerosis and epilepsy&#xD;
&#xD;
          8. Alcohol abuse&#xD;
&#xD;
          9. &quot;Palmar-plantar erythrodysesthesia syndrome&quot; / ulceration of hands or feet&#xD;
&#xD;
         10. Cannot understand written or oral information in Danish&#xD;
&#xD;
         11. Inability to cooperate&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast Cancer mainly affects women.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Laurids Ø Poulsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurids Ø Poulsen, MD, PhD</last_name>
    <phone>+45 97666795</phone>
    <email>laop@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helena Brøckner, Ba.Sc</last_name>
    <phone>+4529702992</phone>
    <email>hbrack15@student.aau.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Northern Jutland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurids Østergaard Poulsen, PhD</last_name>
      <phone>97666795</phone>
      <email>laop@rn.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Carsten Dahl Mørch</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Assessment of nerve fiber excitability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

